Literature DB >> 11504778

Drug synergism: its detection and applications.

R J Tallarida1.   

Abstract

Two drugs that produce overtly similar effects will sometimes produce exaggerated or diminished effects when used concurrently. A quantitative assessment is necessary to distinguish these cases from simply additive action. This distinction is based on the classic pharmacologic definition of additivity that, briefly stated, means that each constituent contributes to the effect in accord with its own potency. Accordingly, the relative potency of the agents, not necessarily constant at all effect levels, allows a calculation using dose pairs to determine the equivalent of either agent and the effect by using the equivalent in the dose-response relation of the reference compound. The calculation is aided by a popular graph (isobologram) that provides a visual assessment of the interaction but also requires independent statistical analysis. The latter can be accomplished from calculations that use the total dose in a fixed-ratio combination along with the calculated additive total dose for the same effect. Different methods may be used, and each is applicable to experiments in which a single drug is given at two different sites. When departures from additivity are found, whether in "two-drug" or "two-site" experiments, the information is useful in designing new experiments for illuminating mechanisms. Several examples, mainly from analgesic drug studies, illustrate this application. Even when a single drug (or site) is used, its introduction places it in potential contact with a myriad of chemicals already in the system, a fact that underscores the importance of this topic in other areas of biological investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504778

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  198 in total

1.  Commentary on neostigmine interactions with non steroidal anti-inflammatory drugs by Miranda et al.

Authors:  Ronald J Tallarida
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

2.  Optimization of drug combinations using Feedback System Control.

Authors:  Patrycja Nowak-Sliwinska; Andrea Weiss; Xianting Ding; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Chih-Ming Ho
Journal:  Nat Protoc       Date:  2016-01-14       Impact factor: 13.491

3.  Effect of the Combination of CI-988 and Morphine on Neuropathic Pain after Spinal Cord Injury in Rats.

Authors:  Junesun Kim; Youngkyung Kim; Suk-Chan Hahm; Young Wook Yoon
Journal:  Korean J Physiol Pharmacol       Date:  2015-02-25       Impact factor: 2.016

4.  Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanislaw J Czuczwar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-14       Impact factor: 3.000

5.  Increased Ca++ uptake by erythrocytes infected with malaria parasites: Evidence for exported proteins and novel inhibitors.

Authors:  Ambuj K Kushwaha; Liana Apolis; Daisuke Ito; Sanjay A Desai
Journal:  Cell Microbiol       Date:  2018-05-21       Impact factor: 3.715

6.  JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.

Authors:  Kian Kani; Carolina Garri; Katrin Tiemann; Paymaneh D Malihi; Vasu Punj; Anthony L Nguyen; Janet Lee; Lindsey D Hughes; Ruth M Alvarez; Damien M Wood; Ah Young Joo; Jonathan E Katz; David B Agus; Parag Mallick
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

7.  Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction.

Authors:  Wei-Chun Chen; Sheng-Yang Wang; Chien-Chih Chiu; Chin-Kai Tseng; Chun-Kuang Lin; Hui-Chun Wang; Jin-Ching Lee
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

8.  Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.

Authors:  David Wai Meng Tai; Thi Bich Uyen Le; Aldo Prawira; Rebecca Zhi Wen Ho; Hung Huynh
Journal:  Hepatol Int       Date:  2021-07-31       Impact factor: 6.047

9.  The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.

Authors:  Stephen E Spurgeon; Greg Coffey; Luke B Fletcher; Russell Burke; Jeffrey W Tyner; Brian J Druker; Andreas Betz; Francis DeGuzman; Yvonne Pak; Dale Baker; Anjali Pandey; Stanley J Hollenbach; Uma Sinha; Marc M Loriaux
Journal:  J Pharmacol Exp Ther       Date:  2012-12-07       Impact factor: 4.030

10.  Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.

Authors:  Amit B Shirode; Paul W Sylvester
Journal:  Biomed Pharmacother       Date:  2009-11-14       Impact factor: 6.529

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.